LOGIN
ID
PW
MemberShip
2025-11-07 10:54
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Multinational Pharmaceuticals, COVID-19 Relief Goods
by
Eo, Yun-Ho
Mar 24, 2020 05:19am
Multinational pharmaceutical companies make donations to overcome COVID-19 crisis. According to the related industry, Korean corporations from multinational pharmaceutical companies such as Novartis, Mundipharma, Bayer, and Ferring, including the Korean Research-based Pharma Industry Association (KRPIA), have supported donations and relief
Company
Listed ovarian anticancer Zejula applies for new indications
by
Eo, Yun-Ho
Mar 23, 2020 06:28am
Anticancer treatment Zejula, listed for pharmaceutical reimbursement last year, is now preparing for expanded label. According to related industry on Mar. 23, Takeda Pharmaceuticals Korea has recently submitted an application to expand reimbursement on DNA repairing Poly ADP-ribose Polymerase (PARP) inhibitor Zejula (niraparib). The
Company
Chong Kun Dang co-market Xofluza with Roche
by
Chon, Seung-Hyun
Mar 23, 2020 06:27am
Chong Kun Dang announced on the 19th that it recently signed a joint sales contract with Roche Korea for domestic distribution of the influenza treatment drug 'Xofluza'. Roche Korea and Chong Kun Dang jointly handle marketing and sales of Xofluza, and Chong Kun Dang is responsible for distribution. Xofluza is a drug used to treat influe
Company
Daewoong vs Allergan, patent dispute for two years
by
Kim, Jin-Gu
Mar 20, 2020 06:25am
The patent dispute between Daewoong Pharmaceutical and Allergan surrounding double-chin reduction treatment 'Belkyra' has not been concluded for the second year. According to the pharmaceutical industry on the 19th, the dispute began in March 2018, two years ago. Daewoong Pharmaceutical filed an invalidation trial of patents for Belkyra
Company
Salespersons got worked up about pharmacy¡¯s poor sales
by
Jung, Hye-Jin
Mar 19, 2020 06:26am
Pharmaceutical industry sales managers are also suffering from the economic downturn in the medical institution caused by the aftermath of COVID-19. This is due to the fact that some retail pharmacies refuse to pay monthly payments to pharmaceutical salesmen due to a decrease in prescriptions. Even at the end of February, quite a few mana
Company
Samsung Biologics, CDO for alzheimer's treatment
by
Lee, Seok-Jun
Mar 19, 2020 06:26am
Samsung Biologics announced on the 17th that it has signed a CDO(Contract Development Organization) partnership with Aprinoia, a Taiwanese company that is developing Alzheimer's treatment. Aprinoia is a Taiwanese bio-venture with specialized technology in developing medical equipment and therapeutics for the diagnosis of degenerative neur
Company
Pharmaceutical industry focuses on Kyung-Hae Lee from GSK
by
Eo, Yun-Ho
Mar 18, 2020 06:35am
Personnel from executives of multinational pharmaceutical companies is on the list of proportional representative candidates for the United Future Party, attracting the attention of the industry. Kyung-Hae Lee(52) is the current vice president of BioGraphene and has been working in the Foreign Cooperation Department of GlaxoSmithKline (GSK
Company
FDA clears Celltrion¡¯s 2nd HIV drug manufacturing plant
by
An, Kyung-Jin
Mar 18, 2020 06:34am
On Mar. 16, Celltrion announced its HIV treatment CT-G07-manufactuing Cheongju facility has passed the U.S. Food and Drug Administration¡¯s (FDA) on-site inspection with no violation. Prior to CT-G07¡¯s global launch, the on-site inspection was carried out to confirm the plant¡¯s manufacturing facility and quality control system. In Janua
Company
2nd anti-CGRP migraine drug Ajovy seeks approval in Korea
by
Eo, Yun-Ho
Mar 17, 2020 06:28am
A second anti-calcitonin gene-related peptide (CGRP) treatment for migraine is preparing for the Korean market. According to pharmaceutical industry sources, Handok Teva has submitted approval application on CGRP targeted migraine treatment Ajovy (fremanezumab) aiming for the Ministry of Food and Drug Safety¡¯s nod by late June. Ajov
Company
Amid COVID-19 industry conflicted with working from home
by
Kim, Jin-Gu
Mar 17, 2020 06:28am
The pharmaceutical industry is in a dilemma of working from home. Pharmaceutical companies that have given an order to work from home to a part or all of the office are conflicted whether to continue or to stop working from home. Depending on companies, some of them have already been working remotely for over a month. But they complain it i
<
351
352
353
354
355
356
357
358
359
360
>